Double Dose of Nuthin’ Hits Biogen After Trial Miss, Pushes to Phase 3 (Because Math)
“Fuhgeddaboudit” - Biogen to its investors, probably…
Somewhere in Biogen's comms department, someone had to write "the study missed its primary endpoint" and "we're advancing to Phase 3" into the same press release and keep a straight face. Biogen's mid-stage Alzheimer's trial had one job, isolate the right dose of its experimental drug, and it came back with a shrug. The lowest dose worked best, the higher doses didn't earn their keep, and no clean line connected them. Everywhere else in pharma that's a miss. Biogen called it "unprecedented" (their word, not the data's) and booked travel to Phase 3.
For context, the drug is diranersen, formerly BIIB080, an antisense oligonucleotide aimed at tau, the protein that knots into tangles in Alzheimer's brains and gets pegged as the disease's actual wrecking crew. The Phase 2 CELIA trial put 416 early-Alzheimer's patients on one of three doses, delivered by spinal injection (a commercial clusterf*ck for another day), across 76 weeks. The goal was a clean dose response: more drug, more effect. CELIA failed to understand that assignment.
To be fair, diranersen did pull something off. It cut tau at every dose, in spinal fluid and on brain scans, and held the cuts for the full trial. It slowed cognitive decline at every dose too, most of all at the lowest one, 60 milligrams every 24 weeks.
Now I’m no expert, but drugs are supposed to do more when you take more of them (this is, in fact, the entire concept of a dose). Diranersen did the opposite, and Biogen hasn't said why. Translation: Less drug, more benefit. A result that makes sense only if you don't think about it too hard.
Friendly reminder, Biogen has chased this disease for years and got two drugs to market, then pulled the first, Aduhelm, after the controversy around its approval became impossible to outrun (sup, Aduhelm). The survivor, Leqembi, targets amyloid, the other prime-suspect protein. Diranersen is the tau bet, and tau has been a drug graveyard. Rival Eli Lilly's own oral tau drug flunked its mid-stage trial outright, no asterisks, just flunked. Next to that, "mixed" is basically sparkles.
However, investors gave Biogen the “that don’t impress me much” treatment. After a quick premarket pop, Biogen shares slid about 5%, because investors can hold a release that says "compelling" and a data set that says "we're honestly not sure" in the same hand. Stifel's Paul Matteis said it cleanest: nobody knows why the dose response wouldn't be linear, and that's an open question central to whether the signal is even real. RBC's Brian Abrahams was savage in his response flagging "scant detail" and "oddities around dose dependence," and didn't move his rating an inch.
Regardless, the company has officially locked the holy trinity of Alzheimer's drug development: tau reduction, cognitive benefit, and a dose. Two of those are real. The third is the trial talking. CELIA, paraphrased, said "I couldn't isolate your dose." Biogen, paraphrased, said "close enough."
Whereas now, diranersen advances to Phase 3, the long, expensive, registration-grade trial, on the strength of a study that whiffed the one thing it was built to measure. Full data lands at the Alzheimer's Association conference in July, which is the part that actually counts. Until then the ask is simple: trust that less is more, trust that the dose math sorts itself out, trust that the win is real. For a drug built to fight memory loss, there’s something almost poetic about everyone “fuhgeddabouditing” the study that didn’t work. Until next time, friends…

At the time of publishing, Stocks.News does not hold positions in companies mentioned in the article.